Statin-Induced Inhibition of MCF-7 Breast Cancer Cell Proliferation is Related to Cell Cycle Arrest and Apoptotic and Necrotic Cell Death Mediated by an Enhanced Oxidative Stress

REFERENCES

• Jakobisiak M., Golab J. Potential antitumor effects of statins. Int J Oncol 2003; 23: 1055–1069
   PubMed Web of Science ®Google Scholar
• Ongini E., Impagnatiello F., Bonazzi A., Guzzetta M., Govoni M., Monopoli A., Del Soldato P., Ignarro L. J. Nitric oxide (NO)-releasing statin derivatives, a class of drugs showing enhanced antiproliferative and antiinflammatory properties. Proc Natl Acad Sci USA 2004; 101: 8497–8502
   PubMed Web of Science ®Google Scholar
• Farmer J. A. Pleiotropic effects of statins. Curr Atherosclero Rep 2000; 2: 208–217
   PubMedGoogle Scholar
• Gotto A. M., Jr., Farmer J. A. Pleiotropic effects of statins: do they matter?. Curr Opin Lipidol 2001; 12: 391–394
   PubMed Web of Science ®Google Scholar
• LaRosa J. C. Pleiotropic effects of statins and their clinical significance. Am J Cardiol 2001; 88: 291–293
   PubMed Web of Science ®Google Scholar
• Schwartz G. G., Olsson A. G., Ezekowitz M. D., Ganz P., Oliver M. F., Waters D., Zeiher A., Chaitman B. R., Leslie S., Stern T. Myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) study investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. J Am Med Assoc 2001; 285: 711–718
   Google Scholar
• Mach F. Toward a role for statins in immunomodulation. Mol Interv 2002; 2: 478–480
   PubMedGoogle Scholar
• Mulhaupt F., Matter C. M., Kwak B. R., Pelli G., Veillard N. R., Burger F., Graber P., Lüscher T. F., Mach F. Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells. Cardiovasc Res 2003; 59: 755–766
   PubMed Web of Science ®Google Scholar
• Bellosta S., Ferri N., Bernini F., Paoletti R., Corsini A. Non-lipid-related effects of statins. Ann Med 2000; 32: 164–176
   PubMed Web of Science ®Google Scholar
• Hess D. C., Fagan S. C. Pharmacology and clinical experience with simvastatin. Expert Opin Pharmacother 2001; 2: 153–163
   PubMedGoogle Scholar
• Graaf M. R., Richel D. J., van Noorden C. J., Guchelaar H. J. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev 2004; 30: 609–641
   PubMed Web of Science ®Google Scholar
• Muck A. O., Seeger H., Wallwiener D. Inhibitory effect of statins on the proliferation of human breast cancer cells. Int J Clin Pharmacol Ther 2004; 42: 695–700
   PubMed Web of Science ®Google Scholar
• Dimitroulakos J., Ye L. Y., Benzaquen M., Moore M. J., Kamel-Reid S., Freedman M. H., Yeger H., Penn L. Z. Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications. Clin Cancer Res 2001; 7: 158–167
   PubMed Web of Science ®Google Scholar
• Horiguchi A., Sumitomo M., Asakuma J., Asano T., Asano T., Hayakawa M. 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, fluvastatin, as a novel agent for prophylaxis of renal cancer metastasis. Clin Cancer Res 2004; 10: 8648–8655
   PubMed Web of Science ®Google Scholar
• Keyomarsi K., Sandoval L., Band V., Pardee A. B. Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res 1991; 51: 3602–3609
   PubMed Web of Science ®Google Scholar
• Mueck A. O., Seeger H., Wallwiener D. Effect of statins combined with estradiol on the proliferation of human receptor-positive and receptor-negative breast cancer cells. Menopause 2003; 10: 332–336
   PubMed Web of Science ®Google Scholar
• Seeger H., Wallwiener D., Mueck A. O. Statins can inhibit proliferation of human breast cancer cells in vitro. Exp Clin Endocrinol Diabetes 2003; 111: 47–48
   PubMed Web of Science ®Google Scholar
• Gronich N., Drucker L., Shapiro H., Radnay J., Yarkosi S., Lishner M. Symvastatin induces death of multiple myeloma cell lines. J Invest Med 2004; 52: 335–344
   PubMed Web of Science ®Google Scholar
• Janosi J., Sebestyen A., Bocsi J., Barna G., Nagy K., Vályi-Nagy I., Kopper L. Mevastatin-induced apoptosis and growth suppression in U266 myeloma cells. Anticancer Res 2004; 24: 1817–1822
   PubMed Web of Science ®Google Scholar
• Liu Z. L., Luo J. M., Dong Z. R., Wang F. X., Zhang X. J., Yang J. C., Du X. Y., Yao L. In vitro effects of mevastatin on the proliferation and apoptosis in human multiple myeloma cell line U266. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2004; 12: 340–345
   PubMedGoogle Scholar
• Shibata M. A., Ito Y., Morimoto J., Otsuki Y. Lovastatin inhibits tumor growth and lung metastatsis in mouse mammary carcinoma model: a p53-independent mitochondrial-mediated apoptotic mechanism. Carcinogene 2004; 25: 1887–1898
   PubMed Web of Science ®Google Scholar
• Czarna M., Jarmuszkiewicz W. Role of mitochondria in reactive oxygen species generation and removal; relevance to signaling and programmed cell death. Postepy Biochem 2006; 52: 145–156
   PubMedGoogle Scholar
• Santillo M., Mondola P., Gioielli A., Serù R., Iossa S., Annella T., Vitale M., Bifulco M. Inhibitors of Ras farnesylation revert the increased resistance to oxidative stress in K-Ras transformed NIH 3T3 cells. Biochem Biophys Res Commun 1996; 229: 739–745
   PubMed Web of Science ®Google Scholar
• Castelazo G., Molotla D., Basavilvazo M. A., Angeles L., Zarate A., Hernandez M. Survival of breast cancer patients treated with inhibitors of the aromatase vs tamoxifen. Ginecol Obstet Mex 2004; 72: 493–499
   PubMedGoogle Scholar
• Valladares A., Salamanca F., Madrigal-Bujaidar E., Arenas D. Identification of chromosomal changes with comparative genomic hybridization in sporadic breast cancer in Mexican women. Cancer Genet Cytogenet 2004; 152: 163–166
   PubMed Web of Science ®Google Scholar
• Denoyelle C., Vasse M., Korner M., Mishal Z., Ganné F., Vannier J. P., Soria J., Soria C. Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic propeties of highly invasive breast cancer cell lines: an in vitro study. Carcinogene 2001; 22: 1139–1148
   PubMed Web of Science ®Google Scholar
• Kueng W., Silber E., Eppenberg V. Quantification of cells cultured on 96-well plates. Analytical Biochem 1989; 186: 16–19
   Web of Science ®Google Scholar
• Zapata E., Ventura J. L., De la Cruz K., Rodriguez E., Damián P., Massó F., Montaño L. F., López-Marure R. Dehydroepiandrosterone inhibits the proliferation of HUVEC by enhancing the expression of p53 and p21, restricting the phosphorylation of RB, and is androgen- and estrogen-receptor independent. FEBS J 2005; 272: 1343–1353
   PubMed Web of Science ®Google Scholar
• Zhang Y. H., Peng H. Y., Xia G. H., Wang M. Y., Han Y. Anticancer effect of two diterpenoid compounds isolated from Annona glabra Linn. Acta Pharmacol Sin 2004; 25: 937–942
   PubMed Web of Science ®Google Scholar
• Rothe G., Valet G. Flow cytometric analysis of respiratory burst activity in phagocytes with hydroethidine and 2′,7′-dichlorofluorescin. J Leukoc Biol 1990; 47: 440–448
   PubMed Web of Science ®Google Scholar
• Haugland R. P. Handbook of fluorescent probes and research chemicals. Molecular Probes Inc., Eugene, OR 1996
   Google Scholar
• Higuchi Y. Glutathione depletion-induced chromosomal DNA fragmentation associated with apoptosis and necrosis. J Cell Mol Med 2004; 8: 455–464
   PubMed Web of Science ®Google Scholar
• Duncan R. E., Lau D., El-Sohemy A., Archer M. C. Geraniol and beta-ionone inhibit proliferation, cell cycle progression, and cyclin-dependent kinase 2 activity in MCF-7 breast cancer cells independent of effects on HMG-CoA reductase activity. Biochem Pharmacol 2004; 68: 1739–1747
   PubMed Web of Science ®Google Scholar
• Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam. Clin Pharmacol 2005; 19: 117–125
   PubMed Web of Science ®Google Scholar
• Lennernas H., Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet 1997; 32: 403–425
   PubMed Web of Science ®Google Scholar
• Lopez E., Sepulveda A. C., Rivera H., Cerecedo F., Valdez M., Villasis M. A. Security and maximal tolerated doses of fluvastatin in pediatric cancer patients. Arch Med Res 1999; 30: 128–131
   PubMed Web of Science ®Google Scholar
• Serajuddin A. T., Ranadive S. A., Mahoney E. M. Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin. J Pharm Sci 1991; 80: 830–834
   PubMed Web of Science ®Google Scholar
• Hamelin B. A., Turgeon J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci 1998; 19: 26–37
   PubMed Web of Science ®Google Scholar
• Li L., Zou L. Sensing, signaling, and responding to DNA damage: organization of the checkpoint pathways in mammalian cells. J Cell Biochem 2005; 94: 298–306
   PubMed Web of Science ®Google Scholar
• Addeo R., Altucci L., Battista T., Bonapace I. M., Cancemi M., Cicatiello L., Germano D., Pacilio C., Salzano S., Bresciani F., Weisz A. Stimulation of human breast cancer MCF-7 cells with estrogen prevents cell cycle arrest HMG-CoA reductase inhibitors. Biochem Biophys Res Commun 1996; 220: 864–870
   PubMed Web of Science ®Google Scholar
• Sutter A. P., Maaser K., Hopfner M., Huether A., Schuppan D., Scherubl H. Cell cycle arrest and apoptosis induction in hepatocellular carcinoma cells by HMG-CoA reductase inhibitors. Synergistic antiproliferative action with ligands of the peripheral benzodiazepine receptor. J Hepatol 2005; 43: 808–816
   Google Scholar
• Holstein S. A., Hohl R. J. Synergistic interaction of lovastatin and paclitaxel in human cancer cells. Mol Cancer Ther 2001; 1: 141–149
   PubMed Web of Science ®Google Scholar
• Kozar K., Kaminski R., Legat M., Kopec M., Nowis D., Skierski J. S., Koronkiewicz M., Jakóbisiak M., Golab J. Cerivastatin demonstrated enhanced antitumor activity against human breast cancer cell lines when used in combination with doxorubicin or cisplatin. Int J Oncol 2004; 24: 1149–1157
   PubMed Web of Science ®Google Scholar
• Chapman-Shimshoni D., Yuklea M., Radnay J., Shapiro H., Lishner M. Simvastatin induces apoptosis of B-CLL cells by activation of mitochondrial caspase 9. Exp Hematol 2003; 31: 779–783
   PubMed Web of Science ®Google Scholar
• Stoll L. L., McCormick M. L., Denning G. M., Weintraub N. L. Antioxidant effects of statins. Timely Top Med Cardiovasc Dis 2005; 9: E1
   PubMedGoogle Scholar
• Hu T. P., Xu F. P., Li Y. J., Luo J. D. Simvastatin inhibits leptin-induced hypertrophy in cultured neonatal rat cardiomyocytes. Acta Pharmacol Sin 2006; 27: 419–422
   PubMed Web of Science ®Google Scholar
• Arai M., Imai H., Koumura T., Yoshida M., Emoto K., Umeda M., Chiba N., Nakagawa Y. Mitochondrial phospholipid hydroperoxide glutathione peroxidase plays a major role in preventing oxidative injury to cells. J Biol Chem 1999; 274: 4924–4933
   PubMed Web of Science ®Google Scholar
• Wei N., Mi M. T., Zhou Y. Influences of lovastatin on membrane ion flow and intracellular signaling in breast cancer cells. Cell Mol Biol Lett 2007; 12: 1–15
   PubMed Web of Science ®Google Scholar
• Xu R., Chen J., Cong X., Hu S., Chen X. Lovastatin protects mesenchymal stem cells against hypoxia- and serum deprivation-induced apoptosis by activation of PI3K/Akt and ERK1/2. J Cell Biochem 2007; 103: 256–269
   Web of Science ®Google Scholar
• Kaufmann P., Török M., Zahno A., Waldhauser K. M., Brecht K., Krähenbühl S. Toxicity of statins on rat skeletal muscle mitochondria. Cell Mol Life Sci 2006; 63: 2415–2425
   PubMed Web of Science ®Google Scholar
• Kim Y. C., Song S. B., Lee M. H., Kang K. I., Lee H., Paik S. G., Kim K. E., Kim Y. S. Simvastatin induces caspase-independent apoptosis in LPS-activated RAW264.7 macrophage cells. Biochem Biophys Res Commun 2006; 339: 1007–1014
   PubMed Web of Science ®Google Scholar
• Koyuturk M., Ersoz M., Altiok N. Simvastatin induces apoptosis in human breast cancer cells: p53 and estrogen independent pathway requiring signalling through JNK. Cancer Lett 2007; 250: 220–228
   PubMed Web of Science ®Google Scholar
• Cafforio P., Dammacco F., Gernone A., Silvestris F. Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis 2005; 26: 883–891
   PubMed Web of Science ®Google Scholar
• Zalatnai A. Review: potential role of cell cycle synchronizing agents in combination treatment modalities of malignant tumors. In Vivo 2005; 19: 85–91
   PubMed Web of Science ®Google Scholar
• Kotamraju S., Williams C. L., Kalyanaraman B. Statin-induced breast cancer cell death: role of inducible nitric oxide and arginase-dependent pathways. Cancer Res 2007; 67: 7386–7394
   PubMed Web of Science ®Google Scholar